Apogee Therapeutics price target raised to $46 from $34 at Stifel

Stifel raised the firm’s price target on Apogee Therapeutics (APGE) to $46 from $34 and keeps a Buy rating on the shares following recent positive Phase 1 data from Viridian Therapeutics’ (VRDN) VRDN-003 and GSK‘s (GSK) acquisition of Aiolos Bio for $1B upfront and $400M in milestones to gain their extended half-life TSLP antibody. The firm views both of these developments as further validation of the underlying half-life extension hypotheses of Apogee and Spyre Therapeutics (SYRE), the analyst tells investors.